Immuneering Corporation is an oncology-focused drug developer based in Cambridge, Massachusetts, working on treatments for various cancer types in the U.S. market. The company's lead program, atebimetinib, is a MEK inhibitor in Phase 3 testing for pancreatic and lung cancers with specific genetic mutations, with partnerships to combine it with other therapies from Regeneron and Eli Lilly. Additionally, Immuneering is advancing envometinib and other inhibitor candidates through earlier-stage clinical development.

entry readiness 63 · MODERATE · exit proximity 0

Value area 4.01–5.28 · 95% of 120d volume overhead · heavy supply